Gastrointestinal Symptoms and Diseases Related to Obesity: An Overview

Gastroenterology Clinics of North America

Volumn 39, Issue 1, 2010, Pages 23-37

  Foxx Orenstein, Amy E ^a  

^a MAYO CLINIC   (United States)

Author keywords

Appetite regulation; GI symptoms; Gut hormone; Obesity

Indexed keywords

ANTIDEPRESSANT AGENT; GASTROINTESTINAL HORMONE; GLUCAGON LIKE PEPTIDE 1; INSULIN; IRON; NARCOTIC AGENT; PEPTIDE YY; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

BARRETT ESOPHAGUS; BODY MASS; BYPASS SURGERY; CANCER RISK; COLON DISEASE; CONSTIPATION; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE ASSOCIATION; FOOD INTAKE; GALLBLADDER CANCER; GASTRIC BANDING; GASTROINTESTINAL SYMPTOM; HEALTH CARE PLANNING; HORMONAL REGULATION; HUMAN; LIVER DISEASE; OBESITY; REVIEW; SATIETY;

BARIATRIC SURGERY; COLORECTAL NEOPLASMS; COMORBIDITY; FATTY LIVER; GASTROINTESTINAL DISEASES; HUMANS; LIVER NEOPLASMS; OBESITY; OBESITY, MORBID;

EID: 77349089751     PISSN: 08898553     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gtc.2009.12.006     Document Type: Review

References (108)

1. Kopelman P.G. Obesity as a medical problem. Nature 404 6778 (2000) 635-643
2. Lew E.A. Mortality and weight: insured lives and the American Cancer Society studies. Ann Intern Med 103 6 Pt 2 (1985) 1024-1029
3. Karra E., Chandarana K., and Batterham R.L. The role of peptide YY in appetite regulation and obesity. J Physiol 587 Pt 1 (2009) 19-25
4. Ogden C.L., Carroll M.D., Curtin L.R., et al. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 295 13 (2006) 1549-1555
5. Freedman D.S., Khan L.K., Serdula M.K., et al. Trends and correlates of class 3 obesity in the United States from 1990 through 2000. JAMA 288 14 (2002) 1758-1761
6. Field A.E., Coakley E.H., Must A., et al. Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Arch Intern Med 161 13 (2001) 1581-1586
7. American College of Gastroenterology. Obesity and digestive disorders. A physician reference. 2008. Available at: www.acg.gi.org/obesity/pdfs/ACG_Obesity_Physician_Reference.pdf. Accessed December 2, 2009.
8. Finkelstein E.A., Trogdon J.G., Cohen J.W., et al. Annual medical spending attributable to obesity: payer- and service-specific estimates. Health Aff 28 5 (2009) w822-w831
9. Delgado-Aros S., Locke III G.R., Camilleri M., et al. Obesity is associated with increased risk of gastrointestinal symptoms: a population-based study. Am J Gastroenterol 99 9 (2004) 1801-1806
10. Crowell M.D., Cheskin L.J., and Musial F. Prevalence of gastrointestinal symptoms in obese and normal weight binge eaters. Am J Gastroenterol 89 3 (1994) 387-391
11. Pourhoseingholi M.A., Kaboli S.A., Pourhoseingholi A., et al. Obesity and functional constipation; a community-based study in Iran. J Gastrointestin Liver Dis 18 2 (2009) 151-155
12. Ayazi S., Hagen J., Chan L., et al. Obesity and gastroesophageal reflux: quantifying the association between body mass index, esophageal acid exposure, and lower esophageal sphincter status in a large series of patients with reflux symptoms. J Gastrointest Surg 13 8 (2009) 1440-1447
13. Cremonini F., Camilleri M., Clark M.M., et al. Associations among binge eating behavior patterns and gastrointestinal symptoms: a population-based study. Int J Obes 33 3 (2009) 342-353
14. Czernichow S., Lee C.M.Y., Barzi F., et al. Efficacy of weight loss drugs on obesity and cardiovascular risk factors in obese adolescents: a meta-analysis of randomized controlled trials. Obes Rev (2009, July 1) [Epub ahead of print]
15. Roux C., Aylwin S., Batterham R., et al. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg 243 1 (2006) 108-114
16. Batterham R.L., Cohen M.A., Ellis S.M., et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 349 10 (2003) 941-948
17. Gutzwiller J.-P., Hruz P., Huber A.R., et al. Glucagon-like peptide-1 is involved in sodium and water homeostasis in humans. Digestion 73 2-3 (2006) 142-150
18. Inui A., Asakawa A., Bowers C.Y., et al. Ghrelin, appetite, and gastric motility: the emerging role of the stomach as an endocrine organ. FASEB J 18 3 (2004) 439-456
19. Williams K.W., Scott M.M., and Elmquist J.K. From observation to experimentation: leptin action in the mediobasal hypothalamus. Am J Clin Nutr 89 3 (2009) 985S-990S
20. Schwartz M.W., and Morton G.J. Obesity: keeping hunger at bay. Nature 418 6898 (2002) 595-597
21. Schwartz M., Woods S., Porte Jr. D., et al. Central nervous system control of food intake. Nature 404 (2000) 661-671
22. Vincent R.P., Ashrafian H., and le Roux C.W. Mechanisms of disease: the role of gastrointestinal hormones in appetite and obesity. Nat Clin Pract Gastroenterol Hepatol 5 5 (2008) 268-277
23. Pliquett R.U., Fuhrer D., Falk S., et al. The effects of insulin on the central nervous system-focus on appetite regulation. Horm Metab Res 38 7 (2006) 442-446
24. Lovshin J.A., and Drucker D.J. Glucagon-like peptides, the central nervous system, and the regulation of energy homeostasis. Curr Med Chem Cent Nerv Syst Agents 3 2 (2003) 73-80
25. Batterham R.L., Cowley M.A., Small C.J., et al. Gut hormone PYY (3-36) physiologically inhibits food intake. Nature 418 6898 (2002) 650-654
26. Cohen M.A., Ellis S.M., Le Roux C.W., et al. Oxyntomodulin suppresses appetite and reduces food intake in humans. J Clin Endocrinol Metab 88 10 (2003) 4696-4701
27. Barrachina M.D., Martinez V., Wang L., et al. Synergistic interaction between leptin and cholecystokinin to reduce short-term food intake in lean mice. Proc Natl Acad Sci U S A 94 19 (1997) 10455-10460
28. Moran T.H., Ameglio P.J., Schwartz G.J., et al. Blockade of type A, not type B, CCK receptors attenuates satiety actions of exogenous and endogenous CCK. Am J Physiol 262 1 Pt 2 (1992) R46-R50
29. Asakawa A., Inui A., Yuzuriha H., et al. Characterization of the effects of pancreatic polypeptide in the regulation of energy balance. Gastroenterology 124 5 (2003) 1325-1336
30. Nakazato M., Murakami N., Date Y., et al. A role for ghrelin in the central regulation of feeding. Nature 409 6817 (2001) 194-198
31. Wren A.M., Seal L.J., Cohen M.A., et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 86 12 (2001) 5992
32. Cummings D.E., Purnell J.Q., Frayo R.S., et al. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 50 8 (2001) 1714-1719
33. Date Y., Kojima M., Hosoda H., et al. Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology 141 11 (2000) 4255-4261
34. Cummings D.E., Weigle D.S., Frayo R.S., et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 346 21 (2002) 1623-1630
35. Hansen T.K., Dall R., Hosoda H., et al. Weight loss increases circulating levels of ghrelin in human obesity. Clin Endocrinol 56 2 (2002) 203-206
36. Bouret S.G. Early life origins of obesity: role of hypothalamic programming. J Ped Gastroenterol Nut 48 (2009) S31-S38
37. Adamo M.R.M., and LeRoith D. Insulin and insulin-like growth factor receptors in the nervous system. Mol Neurobiol 3 (1989) 71-100
38. Sipols A.J., Baskin D.G., and Schwartz M.W. Effect of intracerebroventricular insulin infusion on diabetic hyperphagia and hypothalamic neuropeptide gene expression. Diabetes 44 (1995) 147-151
39. Brennan A.M., and Mantzoros C.S. Drug insight: the role of leptin in human physiology and pathophysiology-emerging clinical applications. Nat Clin Pract Endocrinol Metab 2 6 (2006) 318-327
40. Margetic S., Gazzola C., Pegg G.G., et al. Leptin: a review of its peripheral actions and interactions. Int J Obes Relat Metab Disord 26 11 (2002) 1407-1433
41. Tschop M., Smiley D.L., and Heiman M.L. Ghrelin induces adiposity in rodents. Nature 407 6806 (2000) 908-913
42. Asakawa A., Inui A., Kaga T., et al. Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin. Gastroenterology 120 2 (2001) 337-345
43. Inui A. Ghrelin: an orexigenic and somatotrophic signal from the stomach. Nat Rev Neurosci 2 8 (2001) 551-560
44. Chen H., Simar D., and Morris M.J. Hypothalamic neuroendocrine circuitry is programmed by maternal obesity: interaction with postnatal nutritional environment. PLoS ONE 4 7 (2009) e6259
45. Elias C.F., Lee C., Kelly J., et al. Leptin activates hypothalamic CART neurons projecting to the spinal cord. Neuron 21 6 (1998) 1375-1385
46. Butler AA, Trevaskis JL, Morrison CD. Neuroendocrine control of food intake. In: Bray G, Ryan D, editors. Overweight and the metabolic syndrome: from bench to bedside. Endocrine updates, vol. 26. New York (NY): Springer; 2006. p. 1-10.
47. Heymsfield S.B., Greenberg A.S., Fujioka K., et al. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA 282 16 (1999) 1568-1575
48. Neary M.T., and Batterham R.L. Gut hormones: implications for the treatment of obesity. Pharmacol Ther 124 1 (2009) 44-56
49. Meier J.J., and Nauck M.A. Glucagon-like peptide 1(GLP-1) in biology and pathology. Diabetes Metab Res Rev 21 2 (2005) 91-117
50. Verdich C., Flint A., Gutzwiller J.P., et al. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab 86 9 (2001) 4382-4389
51. le Roux C.W., Batterham R.L., Aylwin S.J.B., et al. Attenuated peptide YY release in obese subjects is associated with reduced satiety. Endocrinology 147 1 (2006) 3-8
52. Onaga T., Zabielski R., and Kato S. Multiple regulation of peptide YY secretion in the digestive tract. Peptides 23 2 (2002) 279-290
53. Feinle-Bisset C., Patterson M., Ghatei M.A., et al. Fat digestion is required for suppression of ghrelin and stimulation of peptide YY and pancreatic polypeptide secretion by intraduodenal lipid. Am J Physiol Endocrinol Metab 289 6 (2005) E948-E953
54. Dakin C.L., Small C.J., Batterham R.L., et al. Peripheral oxyntomodulin reduces food intake and body weight gain in rats. Endocrinology 145 6 (2004) 2687-2695
55. Wynne K., Park A.J., Small C.J., et al. Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial. Int J Obes 30 12 (2006) 1729-1736
56. Baggio L.L., Huang Q., Brown T.J., et al. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology 127 2 (2004) 546-558
57. Gibbs J., Young R.C., and Smith G.P. Cholecystokinin decreases food intake in rats. J Comp Physiol Psychol 84 3 (1973) 488-495
58. Dockray G. Gut endocrine secretions and their relevance to satiety. Curr Opin Pharmacol 4 6 (2004) 557-560
59. West D.B., Fey D., and Woods S.C. Cholecystokinin persistently suppresses meal size but not food intake in free-feeding rats. Am J Physiol 246 5 Pt 2 (1984) R776-R787
60. Dockray G.J. Peptides of the gut and brain: the cholecystokinins. Proc Nutr Soc 46 1 (1987) 119-124
61. Moran T.H. Cholecystokinin and satiety: current perspectives. Nutrition 16 10 (2000) 858-865
62. Gurevich-Panigrahi T., Panigrahi S., Wiechec E., et al. Obesity: pathophysiology and clinical management. Curr Med Chem 16 4 (2009) 506-521
63. Sarac F., Pehlivan M., Celebi G., et al. Effects of sibutramine on thermogenesis in obese patients assessed via immersion calorimetry. Adv Ther 23 6 (2006) 1016-1029
64. Perrio M.J., Wilton L.V., and Shakir S.A.W. The safety profiles of orlistat and sibutramine: results of prescription-event monitoring studies in England. Obesity (Silver Spring) 15 11 (2007) 2712-2722
65. Fich A., Neri M., Camilleri M., et al. Stasis syndromes following gastric surgery: clinical and motility features of 60 symptomatic patients. J Clin Gastroenterol 12 5 (1990) 505-512
66. Lakhani S.V., Shah H.N., Alexander K., et al. Small intestinal bacterial overgrowth and thiamine deficiency after Roux-en-Y gastric bypass surgery in obese patients. Nutr Res 28 5 (2008) 293-298
67. German A.J., Day M.J., Ruaux C.G., et al. Comparison of direct and indirect tests for small intestinal bacterial overgrowth and antibiotic-responsive diarrhea in dogs. J Vet Intern Med 17 1 (2003) 33-43 [see comment]
68. Rutgers H.C., Batt R.M., Elwood C.M., et al. Small intestinal bacterial overgrowth in dogs with chronic intestinal disease. J Am Vet Med Assoc 206 2 (1995) 187-193
69. Sugerman H.J., Kellum J.M., and DeMaria E.J. Conversion of proximal to distal gastric bypass for failed gastric bypass for superobesity. J Gastrointest Surg 1 6 (1997) 517-524 [discussion: 524-6]
70. Tack J., Arts J., Caenepeel P., et al. Pathophysiology, diagnosis and management of postoperative dumping syndrome. Nat Rev Gastroenterol Hepatol 6 10 (2009) 583-590
71. Halverson J.D. Micronutrient deficiencies after gastric bypass for morbid obesity. Am Surg 52 11 (1986) 594-598
72. Dowd J. Nutrition management after gastric bypass surgery. Diabetes Spectrum 18 2 (2005) 82-84
73. Caruana J.A., McCabe M.N., Smith A.D., et al. Incidence of symptomatic gallstones after gastric bypass: is prophylactic treatment really necessary?. Surg Obes Relat Dis 1 6 (2005) 564-567 [discussion: 567-8]
74. Blachar A., Federle M.P., Pealer K.M., et al. Gastrointestinal complications of laparoscopic Roux-en-Y gastric bypass surgery: clinical and imaging findings. Radiology 223 3 (2002) 625-632
75. Maggard M.A., Shugarman L.R., Suttorp M., et al. Meta-analysis: surgical treatment of obesity. Ann Intern Med 142 7 (2005) 547-559
76. Brolin R.E. Bariatric surgery and long-term control of morbid obesity. JAMA 288 22 (2002) 2793-2796
77. Delin C.R., Watts J.M., Saebel J.L., et al. Eating behavior and the experience of hunger following gastric bypass surgery for morbid obesity. Obes Surg 7 5 (1997) 405-413
78. Morinigo R., Moize V., Musri M., et al. Glucagon-like peptide-1, peptide YY, hunger, and satiety after gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab 91 5 (2006) 1735-1740
79. Woods S.C., Schwartz M.W., Baskin D.G., et al. Food intake and the regulation of body weight. Annu Rev Psychol 51 (2000) 255-277
80. Korner J., Inabnet W., Febres G., et al. Prospective study of gut hormone and metabolic changes after adjustable gastric banding and Roux-en-Y gastric bypass. Int J Obes 33 7 (2009) 786-795
81. le Roux C.W., Welbourn R., Werling M., et al. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann Surg 246 5 (2007) 780-785
82. Vincent R.P., and le Roux C.W. Changes in gut hormones after bariatric surgery. Clin Endocrinol 69 2 (2008) 173-179
83. Dixon A.F.R., Dixon J.B., and O'Brien P.E. Laparoscopic adjustable gastric banding induces prolonged satiety: a randomized blind crossover study. J Clin Endocrinol Metab 90 2 (2005) 813-819
84. Cummings D.E., Overduin J., Foster-Schubert K.E., et al. Role of the bypassed proximal intestine in the anti-diabetic effects of bariatric surgery. Surg Obes Relat Dis 3 2 (2007) 109-115
85. Dixon J.B., O'Brien P.E., Playfair J., et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA 299 3 (2008) 316-323
86. Talley N.J., Quan C., Jones M.P., et al. Association of upper and lower gastrointestinal tract symptoms with body mass index in an Australian cohort. Neurogastroenterol Motil 16 4 (2004) 413-419
87. Levy R.L., Linde J.A., Feld K.A., et al. The association of gastrointestinal symptoms with weight, diet, and exercise in weight-loss program participants. Clin Gastroenterol Hepatol 3 10 (2005) 992-996
88. Nguyen D.M., and El-Serag H.B. The big burden of obesity. Gastrointest Endosc 70 4 (2009) 752-757
89. El-Serag H.B., Graham D.Y., Satia J.A., et al. Obesity is an independent risk factor for GERD symptoms and erosive esophagitis. Am J Gastroenterol 100 6 (2005) 1243-1250
90. Friedenberg F.K., Xanthopoulos M., Foster G.D., et al. The association between gastroesophageal reflux disease and obesity. Am J Gastroenterol 103 8 (2008) 2111-2122
91. Hampel H., Abraham N.S., and El-Serag H.B. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med 143 3 (2005) 199-211
92. El-Serag H. The association between obesity and GERD: a review of the epidemiological evidence. Dig Dis Sci 53 9 (2008) 2307-2312
93. Renehan A.G., Tyson M., Egger M., et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371 9612 (2008) 569-578
94. Corley D.A., Kubo A., and Zhao W. Abdominal obesity, ethnicity and gastro-oesophageal reflux symptoms. Gut 56 6 (2007) 756-762
95. Edelstein Z.R., Farrow D.C., Bronner M.P., et al. Central adiposity and risk of Barrett's esophagus. Gastroenterology 133 2 (2007) 403-411
96. Corley D.A., Kubo A., Levin T.R., et al. Abdominal obesity and body mass index as risk factors for Barrett's esophagus. Gastroenterology 133 1 (2007) 34-41
97. Cook M.B., Greenwood D.C., Hardie L.J., et al. A systematic review and meta-analysis of the risk of increasing adiposity on Barrett's esophagus. Am J Gastroenterol 103 2 (2008) 292-300
98. Shaffer E.A. Gallstone disease: epidemiology of gallbladder stone disease. Best Pract Res Clin Gastroenterol 20 6 (2006) 981-996
99. Li V.K.M., Pulido N., Fajnwaks P., et al. Predictors of gallstone formation after bariatric surgery: a multivariate analysis of risk factors comparing gastric bypass, gastric banding, and sleeve gastrectomy. Surg Endosc 23 7 (2009) 1640-1644
100. Clark J.M., Brancati F.L., and Diehl A.M. Nonalcoholic fatty liver disease. Gastroenterology 122 6 (2002) 1649-1657
101. Marceau P., Biron S., Hould F.S., et al. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab 84 5 (1999) 1513-1517
102. Diehl A.M. Hepatic complications of obesity. Gastroenterol Clin North Am 34 1 (2005) 45-61
103. Halverson J.D., Wise L., Wazna M.F., et al. Jejunoileal bypass for morbid obesity. A critical appraisal. Am J Med 64 3 (1978) 461-475
104. Dhabuwala A., Cannan R.J., and Stubbs R.S. Improvement in co-morbidities following weight loss from gastric bypass surgery. Obes Surg 10 5 (2000) 428-435
105. Wanless I.R., and Lentz J.S. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 12 5 (1990) 1106-1110
106. Larsson S.C., and Wolk A. Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies. Br J Cancer 97 7 (2007) 1005-1008
107. Ansary Moghaddam A., Wodward M., and Huxley R. Obesity and risk of colorectal cancer: a meta-analysis of 31 studies with 70,000 events. Cancer Epidemiol Biomarkers Prev 16 (2007) 2533-2547
108. Siddiqui A., Pena Sahdala H.N., Nazario H.E., et al. Obesity is associated with an increased prevalence of advanced adenomatous colon polyps in a male veteran population. Dig Dis Sci 54 7 (2009) 1560-1564